August 21st, 2024 | 07:00 CEST
Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?
The recent outbreak of monkeypox has once again highlighted the critical importance of a rapid and effective response to emerging health threats. This situation highlights the significant role of the biotech and pharmaceutical industries in addressing such challenges. Some companies are focused on combating infectious diseases such as monkeypox, while others are developing innovative therapies for chronic, severe, or rare diseases. Today, we look at three companies committed to improving people's health.
time to read: 4 minutes
|
Author:
Armin Schulz
ISIN:
BAYER AG NA O.N. | DE000BAY0017 , CARDIOL THERAPEUTICS | CA14161Y2006 , EVOTEC SE INH O.N. | DE0005664809
Table of contents:
![David Elsley, CEO, Cardiol Therapeutics Inc. David Elsley, CEO, Cardiol Therapeutics Inc.](https://news.financial/media/pages/interviews/cardiol-therapeutics-inc-ceo-david-elsley-on-new-therapies-for-acute-myocarditis-and-recurrent-pericarditis/9d3a7d8ed3-1706559938/david-elsley-54x54-crop-q85.jpg)
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
Tag cloud
Shares cloud
Bayer - New pharma products with good results
Bayer has recently made significant progress in its product development. Elinzanetant, a non-hormonal treatment for menopausal symptoms, has received a marketing authorization application from the FDA following positive results from Phase III studies. At the same time, finerenone has shown significant cardiovascular benefits for patients with heart failure in the Phase III study FINEARTS-HF. These developments underscore Bayer's commitment to bringing innovative and effective therapies to market that can significantly improve both healthcare and patient care.
In Q2 2024, Bayer achieved revenue of EUR 11.144 billion, an increase of 3.1% compared to the previous year. However, EBITDA before exceptionals decreased by 16.5% to EUR 2.111 billion. Fortunately, free cash flow increased to EUR 1.273 billion, compared with a negative figure of EUR -473 million in the previous year. In addition, Bayer reduced its net financial debt by 1.9% to EUR 36.760 billion. These mixed results reflect the Company's challenges and progress and highlight the need to continue both revenue growth and efficiency improvements.
For 2024, Bayer has confirmed its growth forecast, with revenues in Crop Science expected to vary between -1% and +3% and for Pharmaceuticals between 0% and +3%. For Consumer Health, the Company expects growth of between 3% and 6%. Despite the existing challenges, Bayer remains optimistic and is focusing on stable development. The focus remains on the launch of new products such as elinzanetant and finerenone, which could be key drivers for future growth. On the other hand, the legal disputes must be settled in order to enter calmer waters. The share is currently trading at EUR 28.37.
Cardiol Therapeutics - Positive Phase II results
Cardiol Therapeutics is a clinical-stage company focused on the research and development of anti-inflammatory and anti-fibrotic therapies in the treatment of heart disease. The Company's lead product, CardiolRx™, an orally administered formulation, aims to effectively inhibit inflammatory processes that can lead to rare diseases such as myocarditis and pericarditis. Cardiol has received clinical trial approval from the US Food and Drug Administration (FDA) to evaluate the efficacy and safety of CardiolRx™ in a Phase II pilot study specifically targeting the treatment of recurrent pericarditis and another Phase II study aimed at combating myocarditis.
The ongoing MAvERIC-Pilot study is investigating the effect of CardiolRx™ in 27 patients with symptomatic recurrent pericarditis. Initial results showed a significant reduction in pain reported by patients within eight weeks and normalization of inflammatory markers in 80% of participants with elevated CRP. In the study, the drug was considered safe and 89% of participants prolonged treatment. These results suggest that treatment with CardiolRx™ offers comparable outcomes to established biologic therapies, strengthening the prospect of entry into the Phase III study. Phase III is anticipated to provide a broader, non-immunosuppressive treatment option for patients.
Based on the positive study results, the market is optimistic that the shares have further potential. The analysts recommend the share as a "Buy" with an average price target of CAD 9.75, which is roughly equivalent to USD 7.15. The share price has risen by almost 280% at its peak this year and has since consolidated. At a share price of USD 1.95 on the NASDAQ, the gain is still 130% since the beginning of the year.
Evotec - Quarterly figures after the profit warning
The Hamburg-based drug discovery company Evotec surprised the market at the beginning of August with a significant reduction in its profit forecast. The Company now expects EBITDA of between EUR 15 and 35 million for the financial year 2024. This represents a considerable decrease compared to the previous year when adjusted EBITDA amounted to EUR 66.4 million. Evotec is facing delayed order intake and continued high-cost pressure. The announcement led to a significant drop in the share price, which has recently recovered slightly.
Amidst the negative news, there were also positive developments: The strategic partnership with Bristol Myers Squibb is showing progress. Evotec received a payment of USD 25 million for further research in the field of neurodegeneration. The collaboration, initiated in 2016, aims to develop novel treatments for neurodegenerative diseases. This partnership adds significantly to Evotec's scientific and commercial potential by generating promising pipeline projects that have progressed to the clinical stage.
The quarterly results on August 14 reflect the challenges facing the Company. Although revenue rose by 7% to EUR 182.1 million, the loss in Q2 amounted to almost EUR 95 million, around six times higher than in the same period last year. The slow conversion of orders into sales and the high proportion of fixed costs had a noticeable negative impact on earnings. Despite these setbacks, the management emphasizes the progress made in the realignment towards profitable growth. It expects long-term positive effects from the measures introduced to reduce costs and increase efficiency. The share is currently available for EUR 5.75.
The outbreak of monkeypox has once again highlighted the importance of the biotech and pharmaceutical industry. Bayer has made significant progress with new drugs such as elinzanetant and finerenon despite mixed results. Cardiol Therapeutics impresses with positive Phase II data for CardiolRx™, which bodes well for future developments. Evotec is facing lowered profit forecasts but continues to make advances in its partnership with Bristol Myers Squibb. Overall, it is clear that innovative developments and strategic partnerships are key to advancing the healthcare sector and overcoming future challenges.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.